Infections

Skin and Connective Tissue Diseases

All Conditions

Neoplasms

Digestive System Diseases

Ear, Nose, and Throat Diseases

Musculoskeletal Diseases

Respiratory Tract (Lung and Bronchial) Diseases

Mouth and Tooth Diseases

Rare Diseases

Herpes Simplex

Esophageal Neoplasms

Head and Neck Neoplasms

Virus Diseases

Otorhinolaryngologic Neoplasms

Nose Neoplasms

Laryngeal Neoplasms

Pharyngeal Neoplasms

Laryngeal Diseases

Respiratory Tract Diseases

Respiratory Tract Neoplasms

Otorhinolaryngologic Diseases

Pharyngeal Diseases

Stomatognathic Diseases

Esophageal Cancer

Laryngeal Cancer

All Drugs and Chemicals

Muromonab-CD3

Every 7-14 days,1-2 ml R130 （concentration of 1x10\^8 plaque-forming Units/mL,PFU/mL）will be injected intratumoral in patients with relapsed/refractory head and neck cancer

R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11

Recombinant oncolytic herpes simplex virus type 1 (R130)

Feng Pan, MD

Haitao Wu, Ph.D

Jian Chen

Haitao Wu, Phd

9 participants are expected to be enrolled for this open，single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with relapsed/refractory head and neck cancer.

A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Relapsed/Refractory Head and Neck Cancer

A Clinical Safety and Efficacy Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Head and Neck Cancer

To characterize the safety profile of R130 injection in patients with relapsed/refractory head and neck cancer as measured by the incidence of Grade ≥ 3 Common Terminology Criteria for Adverse Events, version 5.0 (CTCAE v5.0)

Detection of increased systemic immune Response markers in sera (IL2,IL4,IL6,IL8,IL10,TNFa，IFNγ, etc.) and peripheral blood mononuclear cells by multi-Color fluorescence-activated cell sorting (FACS)

Evaluate the efficacy endpoints of DCR by the investigator with RECIST v1.1 and iRECIST

Evaluate the efficacy endpoints of DOR by the investigator with RECIST v1.1 and iRECIST

Eye & ENT Hospital of Fudan University

Shanghai Yunying Medical Technology

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Relapsed/Refractory Head and Neck Cancer	NCT05830240	Head and Neck C... Esophageal Canc... Otorhinolaryngo... Ear Cancer Nose Cancer Laryngeal Cance... Pharyngeal Canc...	Recombinant onc...	18 Years - 75 Years	Shanghai Yunying Medical Technology
A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Relapsed/Refractory Head and Neck Cancer	NCT05830240	Head and Neck C... Esophageal Canc... Otorhinolaryngo... Ear Cancer Nose Cancer Laryngeal Cance... Pharyngeal Canc...	Recombinant onc...	18 Years - 75 Years	Shanghai Yunying Medical Technology

Spots Global Cancer Trial Database for ear cancer

Every month we try and update this database with for ear cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for ear cancer

Every month we try and update this database with for ear cancer cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for ear cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.